Acticor Biotech

About the deal

Paris, France, March 15, 2024 – 8:00 am CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT – the «  »Company » »), a clinical-stage biotechnology company developing glenzocimab, a novel drug for the treatment of cardiovascular emergencies, in particular stroke, today announces the successful completion of its capital increase for a total gross amount of 8 million euros, through the issue of 2,566,086 new shares at a price of € 3.13 per share.

Following the success of the transaction, ACTICOR BIOTECH will use the proceeds of the capital increase to pursue its development plan in the emergency treatment of stroke. The Company mainly plans to use the funds raised to:
• Finalization of phase 2/3 of the ACTISAVE study, with results expected in Q2 2024;
• Validation of the global registration plan with the regulatory authorities (FDA and EMA); and
• Preparation of the additional studies required to register glenzocimab in Europe and the United States.